drugset / Trial / NCT02336139

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

NCT02336139

Phase 2 Completed 103 enrolled Kirby Institute
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following sofosbuvir/GS-5816 therapy for 12 weeks in people with chronic HCV infection and recent injection drug use.

Timeline

Start
2016-03-16
Primary completion
2017-04-17
Completion
2018-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sofosbuvir Small molecule 400 mg Oral
Subject velpatasvir Other / unclassified 100 mg Oral